+93.6%
EOG vs MRNA
+521.0%
-427.4%
-71.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.3% | +0.7% | -0.4% | +0.3% |
| 7D | +1.0% | -8.2% | +9.3% | +1.1% |
| 30D | +2.8% | +125.6% | -122.7% | +1.6% |
| 3M | +5.9% | +197.1% | -191.2% | +4.1% |
| 6M | +17.1% | +148.5% | -131.4% | +15.4% |
| YTD | +43.9% | +363.3% | -319.4% | +40.1% |
| 1Y | +26.9% | +462.0% | -435.1% | +23.0% |
| 3Y | +23.6% | +26.9% | -3.4% | +21.0% |
| 5Y | +178.1% | -69.6% | +247.7% | +172.7% |
| All | +93.6% | +521.0% | -427.4% | +69.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling